20.72

3.34% 0.67

After Hours: 20.77 0.05 +0.24%

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $20.72, with a volume of 2.02M. It is up +3.34% in the last 24 hours and up +19.84% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Previous Close:

$20.05

Open:

$20.215

24h Volume:

2.02M

Relative Volume:

1.14

Market Cap:

$2.48B

Revenue:

$59.61M

Net Income/Loss:

$-262.14M

P/E Ratio:

-5.2857

EPS:

-3.92

Net Cash Flow:

$-247.49M

1W Performance:

+4.86%

1M Performance:

+19.84%

6M Performance:

+64.58%

1Y Performance:

+111.64%

1-Day Range:

$20.16

$21.06

1-Week Range:

$19.41

$21.56

52-Week Range:

$8.03

$21.56

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (637)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

342

Twitter

@ArcutisBio

Next Earnings Date

2024-12-06

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	20.72	2.40B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

12:13 PM

How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com

12:13 PM

11:23 AM

Should you wait for a breakout in Arcutis Biotherapeutics Inc.July 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com

11:23 AM

10:33 AM

Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com

10:33 AM

10:30 AM

Is Arcutis Biotherapeutics Inc. stock poised for growth2025 Momentum Check & Weekly Sector Rotation Insights - newser.com

10:30 AM

10:26 AM

Can Arcutis Biotherapeutics Inc. hit a new high this monthEarnings Overview Summary & Free High Return Stock Watch Alerts - newser.com

10:26 AM

10:01 AM

Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com

10:01 AM

09:42 AM

Sentiment analysis tools applied to Arcutis Biotherapeutics Inc.Market Growth Report & Daily Market Momentum Tracking - newser.com

09:42 AM

How to interpret RSI for Arcutis Biotherapeutics Inc. stock2025 Market WrapUp & Safe Capital Growth Tips - newser.com

09:42 AM

01:42 AM

What the charts say about Arcutis Biotherapeutics Inc. todayPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com

01:42 AM

Oct 12, 2025

Arcutis Biotherapeutics Hits New 52-Week High of $21.55 - Markets Mojo

Oct 12, 2025

Oct 11, 2025

Arcutis Biotherapeutics reaches milestone recognized by Nasdaq - Traders Union

Oct 11, 2025

Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Oct 11, 2025

Oct 10, 2025

Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com

Oct 10, 2025

Oct 08, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat

Oct 08, 2025

Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia

Oct 08, 2025

Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com

Oct 08, 2025

Oct 07, 2025

Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com

Oct 07, 2025

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace

Oct 07, 2025

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛

Oct 07, 2025

Oct 06, 2025

FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria

Oct 06, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat

Oct 06, 2025

Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo

Oct 06, 2025

FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics

Oct 06, 2025

Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com

Oct 06, 2025

ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Dermatitis - GuruFocus

Oct 06, 2025

FDA approves ZORYVE cream for atopic dermatitis in young children - Investing.com

Oct 06, 2025

Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 - Quiver Quantitative

Oct 06, 2025

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (2025-10-06) - Seeking Alpha

Oct 06, 2025

Fishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Oct 06, 2025

Oct 05, 2025

What drives Arcutis Biotherapeutics Inc stock priceMarket Sentiment Extremes & Ride the Wave of Market-Beating Growth - earlytimes.in

Oct 05, 2025

Is Arcutis Biotherapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com

Oct 05, 2025

Oct 04, 2025

Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest - Yahoo Finance

Oct 04, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider Selling - Defense World

Oct 04, 2025

Oct 03, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider Selling - MarketBeat

Oct 03, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat

Oct 03, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 Shares - MarketBeat

Oct 03, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 Shares - MarketBeat

Oct 03, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 03, 2025

Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener

Oct 03, 2025

94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years - Stock Titan

Oct 03, 2025

Will Arcutis Biotherapeutics Inc. stock split attract more investorsOptions Play & Weekly Chart Analysis and Guides - newser.com

Oct 03, 2025

Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer - Markets Mojo

Oct 03, 2025

Oct 02, 2025

Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162% - Markets Mojo

Oct 02, 2025

AMI Asset Management Corp Sells 94,839 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Oct 02, 2025

Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27% - simplywall.st

Oct 02, 2025

Oct 01, 2025

Q4 2025 FDA Preview: 10 Decisions to Watch - HCPLive

Oct 01, 2025

Arcutis Biotherapeutics Hits New 52-Week High of $19.36 - Markets Mojo

Oct 01, 2025

Arcutis Biotherapeutics Hits Day High with Strong 7.29% Intraday Surge - Markets Mojo

Oct 01, 2025